Personalizing Prostate Cancer Screening May Improve Detection Accuracy
The accuracy of PSA in prostate cancer screening can be improved by accounting for genetic factors that are not associated with cancer.
Category: Prostate
Prostate
Latest
Prostate
Latest
Cleveland Diagnostics and Quest Diagnostics Expand Access to Prostate Cancer Test
Cleveland Diagnostics announced an agreement with Quest Diagnostics to expand patient access to its novel prostate cancer test, IsoPSA.
Prostate
Latest
New Prediction Algorithm Could Help Target Risk of Developing Prostate Cancer
Cambridge scientists have created a comprehensive tool for predicting an individual's risk of developing prostate cancer.
Genomic Testing Can Identify African American Prostate Cancer Patients Who Have High-Risk Disease
A new study investigated genomic biomarkers associated with aggressive disease in African American men with prostate cancer.
Read More
Considering Genetic Risk in Prostate Cancer Referrals Could Lead to Early Diagnosis
Men at the highest risk for prostate cancer could be fast-tracked for investigation if their genetic risk was considered in general practice.
Read More
Urine-Based Molecular Test for Prostate Cancer Available
miR Sentinel is a novel, urine-based molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm.
Read More
Nanostics’ Prostate Test Helps Assess Patient Biopsy Needs, Study Shows
Nanostics’ ClarityDX Prostate test is designed to improve the accuracy of detecting significant prostate cancer in men at risk of the disease.
Read More
Fewer PSA Tests May Cut Overdiagnosis But Miss Aggressive Prostate Cancer Cases
The incidence of more aggressive prostate cancer cases that are higher-grade disease and metastasis at diagnosis have risen.
Read More
Prostate Cancer Detection Improved by Accounting for Genetics that Cause PSA Level Variations
PSA screening for prostate cancer could be improved by accounting for genetic factors that cause PSA changes not associated with cancer.
Read More
Verily & Lumea Partner to Advance Digital Pathology for Prostate Cancer
Digital pathology solutions provider Lumea and Verily, an Alphabet a precision health company,...
Read More
Metastatic Prostate Cancer on the Rise as Screenings Decreased
The incidence rate of metastatic prostate cancer increased for men 45 and older and coincides with recommendations against screenings.
Read More
Semiconductor Microchip Detects Prostate Cancer Markers with High Sensitivity
Researchers have developed a semiconductor sensor capable of detecting ultra-low concentrations of tumor markers, on chips made using micromachine tech.
Read More
FDA Grants Breakthrough Designation for Early-Stage Prostate Cancer Detection Blood Test
The FDA has granted Breakthrough Device Designation for Datar Cancer Genetics’ TriNetra-Prostate blood test to detect early-stage prostate cancer.
Read More
How the Pandemic Impacted Prostate Cancer Diagnostics
A senior medical director for Quest Diagnostics discusses how the pandemic impacted prostate cancer diagnostics and how it will impact clinical labs.
Read More
Portable Prostate Cancer Test Aims to Reach Underserved Men
A portable and rapid prostate cancer screening kit could provide early warning to populations with higher incidence of prostate cancer.
Read More
Poorer Prostate Cancer Survival Rates Associated with Novel Protein Markers
A new study has identified novel cancer markers in patients with aggressive prostate cancer that indicate poorer survival.
Read More
Long-Term Study Validates Genomic Assay for Prostate Cancer
Exact Sciences has announced results underscoring the importance of adverse pathology as a reliable and critical endpoint for prostate cancer patients.
Read More
PSA Testing Rates Increased After National Guidelines Revised
In a large study, more men received a prostate-specific antigen or PSA test to detect prostate cancer following revisions by the USPSTF on screening.
Read More